Results 121 to 130 of about 6,909,064 (256)

Impact of Japan's 2024 Physician Work‐Style Reform on Pediatric Hematology–Oncology: Educational Implications in a 2‐Year Survey

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Japan's 2024 physician work‐style reform introduced legally binding limits on physicians’ working hours, but its impact on education and workforce sustainability in pediatric hematology–oncology (PHO) remains unclear. Procedure We conducted a repeated cross‐sectional study with structured quantitative items and free‐text responses ...
Kiyohiko Kaizu, Masaharu Akiyama, Toshikazu Itabashi, Jun Hayakawa, Takahiro Kikuchi, Ryohei Fukunaga, Katsuyoshi Koh, Takahiro Ueda   +7 more
wiley   +1 more source

Application of Language Models for the Analysis of Adverse Drug Events in Pharmaceutical Research and Development: Scoping Review. [PDF]

JMIR AI
Schreier O, Yazdani A, Galdadas I, Kabak R, Gervasio FL, Mu G, Teodoro D.   +6 more
europepmc   +1 more source

Reassessing Bone Marrow Aspirate and Trephine Biopsies in Staging for Paediatric and Young Adult Patients With Ewing Sarcoma and Rhabdomyosarcoma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) are aggressive malignancies in children and adolescents where metastases impact prognosis. 18F‐fluoro‐2‐deoxy‐d‐glucose positron emission tomography/computed tomography (FDG‐PET/CT) and bone marrow aspirate and trephine biopsies (BMAT) are used to identify disease involvement.
Imogen Andrews, Bruce Goodwin, Lauren Buckley, Rick Walker   +3 more
wiley   +1 more source

Artificial intelligence in drug research and development: a review of methods and applications in drug repurposing. [PDF]

Brief Bioinform
Zielińska A, Fornalik M, Szczepaniak M, Gimla M, Lemańska A, Cielecka-Piontek J, Souto EB.   +6 more
europepmc   +1 more source

Infant Embryonal CNS Tumors: Molecular Insights and Treatment Considerations for Contemporary Pediatric Neuro‐Oncology

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Embryonal tumors comprise the majority of malignant central nervous system (CNS) neoplasms diagnosed in children under 3 years of age. Compared with their counterparts in older children, these tumors exhibit distinct molecular biology and a more aggressive clinical phenotype, while their management is complicated by the heightened ...
Sudarshawn Damodharan, Mariah Wright‐Nadkarni, Mohamed S. Abdelbaki, Girish Dhall   +3 more
wiley   +1 more source

Tensions in patient involvement and engagement in health research and development: a qualitative interview study with key actors. [PDF]

Res Involv Engagem
Kiani K, Phillips Ingvason Nguyễn V, Siira E, Wallengren C, Wolf A, Björkman I.   +5 more
europepmc   +1 more source

From fellows to leaders: lessons learned from the WHO/TDR Clinical Research and Development Fellowship (1999-2021). [PDF]

Public Health Action
Vahedi M, Assefa DG, Casamitjana N, Launois P.   +3 more
europepmc   +1 more source

A Bibliometric Analysis of Publications in Uremic Toxins From 1991 to 2024

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Uremic toxins are a growing area of research in nephrology, with significant implications in the progression and treatment of chronic kidney disease (CKD) and the management of end‐stage kidney disease (ESKD). This bibliometric analysis aims to evaluate the global research trends, key contributors, and the impact of publications in ...
Yuh‐Shan Ho, Karim M. Soliman, Wisit Cheungpasitporn, Wannasit Wathanavasin, Ahmed Daoud, Ahmed I. Kamal, Balázs Szamosfalvi, Tibor Fülöp   +7 more
wiley   +1 more source

Therapeutic Apheresis in Nigeria: A Multi‐Center Summary of Abstracts From the Inaugural Nigerian Society for Apheresis Scientific Meeting

Therapeutic Apheresis and Dialysis, EarlyView.
ABSTRACT Background Therapeutic apheresis (TA) is an established treatment modality for hematologic, neurologic, and immunologic disorders, yet access remains severely limited in sub‐Saharan Africa. Donor apheresis, including platelet apheresis collection from healthy donors, represents an important complementary modality supporting blood product ...
Nosa Bazuaye, Chimezie Okwuonu, Evelyn Idam, Folasade Adelekan‐Popoola, Shakirat Gold‐Olufadi, Olufunto Olufela Kalejaiye, Abdullateef Ogala, Zinnah Aloziem, Blossom Amamchukwu, Patience Elimia, Mkpoikanabasi Obot‐Obot, Henry Mbakwe, Praises Maduagwuna, Olatunji Akinrodoye, Chiamaka Anyanwu, Benjamin Anyanwu, Adedamola Akinsiku, Oluwatoyin A. Akinsiku, Muzamil O. Hassan, Fatiu A. Arogundade, Olalekan E. Ojo, Homayemem Weli, Jesupelumi Adenihun, Aderemi Adelaja, Ebun Bamgboye, Olalekan Olatise, Ade E. Faponle, Ayoola Odeyemi, Michael Muoka, Stephen Asaolu, Qudrat Busari, Blessing Dawudu, Michael Naiyeju, Rasheed A. Balogun   +33 more
wiley   +1 more source

Research and development prospects of TRIM65. [PDF]

J Cancer Res Clin Oncol
Deng NH, Chen JH, Tian Z, Quan SB.
europepmc   +1 more source